Search term is required Close Search

Deciphering the Disease-Modifying Treatments for Alzheimer’s Disease

There is no charge to attend this webinar.
Alzheimers Puzzle

June 13, 2024 12:00pm – 1:30pm (CT) Online

CE: 1.5 contact hours
Includes 0.5 hours of pharmacology

This live webinar, presented by the American Association of Nurse Practitioners® (AANP), provides information about the emergence and availability of disease-modifying therapies for Alzheimer’s disease (AD) that make it critically important to diagnose and treat the disease early — before irreversible neurological damage accumulates. In this webinar, nurse practitioner (NP) experts Drs. Carolyn Clevenger and Raymond Romano discuss the new paradigm of disease modification in AD, provide an overview of available and emerging treatment options, walk you through how to make a diagnosis of AD and present a case study. A recording of the webinar will be made available as an on-demand presentation within a week of the live event.

Event Details
  • Webinar Details

    When: June 13, 2024, 1-2:30 p.m. ET (12-1:30 p.m. CT).

    Where: Online via the AANP CE Center.

    Cost: Free for AANP members and non-members.

    CE Credit: This activity is approved for 1.5 contact hours of CE, which includes 0.5 hours of pharmacology, by the American Association of Nurse Practitioners® (AANP). This activity was planned in accordance with AANP Accreditation Standards and Policies.

    Register Now

    About the Webinar

    The prevalence of AD in the United States is predicted to double from about 6.7 million in 2023 to 13.8 million by 2050. Historically, diagnosis was made quite late in the disease state, but with the advent of disease modifying treatments for AD — which confer their benefit in the early stages of disease — comes a paradigm shift in the way that health care providers think about this disease. In this program, faculty experts Drs. Carolyn Clevenger and Raymond Romano discuss the importance of early diagnosis, the data supporting the efficacy and safety of disease-modifying therapy for AD and the role of the primary care provider. Drs. Clevenger and Romano will be available to answer your questions in the live Q and A session following the webinar presentation. They have created an educational tool for you to reference as you adjust your practice to this new paradigm of the importance of early diagnosis and referral.


    • Discuss the importance of early diagnosis of AD with regard to disease-modifying treatment benefits.
    • Examine the clinical trial data supporting the efficacy and safety of disease-modifying treatments in the treatment of AD.
    • Summarize strategies for improving patient access to disease-modifying therapies for AD.

    This webinar is supported by an independent educational grant from Eisai.

  • Speakers
    Carolyn Clevenger

    Carolyn K. Clevenger, DNP, GNP-BC, FAANP, FGSA, FAAN

    Dr. Carolyn Clevenger is the founder and director of Emory Nursing’s Integrated Memory Care (IMC) practice. The IMC is a nurse-led primary care practice for people living with dementia with a clinic location as well as senior living community programs across metro Atlanta. The new model of care has been recognized as a Patient-Centered Medical Home, an Age Friendly Health System, and a Best Practice exemplar for patient- and family-centered care. The comprehensive dementia care model has been featured in Health Affairs, ABC News and Forbes this year.

    Raymond Romano, PhD, MPH, RN, FNP-BC

    Raymond Romano, PhD, MPH, RN, FNP-BC

    Dr. Raymond Romano is a family NP with experience in research and quality improvement. His focus is on health services research, and his specific interests are in the detection, diagnosis and care of dementia in the primary care setting. He earned his bachelor’s degree in biology at Marymount Manhattan College, his master’s degree in public health from Boston University and his master’s degree in nursing from Vanderbilt University. He completed his PhD at the University of Tennessee Health Science Center during which he studied how alteration in the pain experience differs in those at risk for developing AD. He currently works at the Vanderbilt Memory and Alzheimer’s Center where he conducts clinical assessments for the Center’s longitudinal studies and supports the strategic development of outreach and recruitment activities. Additionally, he provides care for people living with dementia at Vanderbilt University Medical Center.